

Phase 2b randomized, placebo-controlled, double-blind trial. Patients with moderate-severe ulcerative colitis were randomized to abrilumab (anti- $\alpha 4\beta 7$  antibody) SC (7mg, 21 mg or 70 mg) on day 1 weeks 2 and 4 and q4w; 210mg on day one or placebo.

**Primary endpoint:** Remission (Total Mayo score  $\leq 2$  points) for the 2 highest dosages at week 8


#### Results: N=354

- Remission at week 8: 4.3% placebo ; 13.3% ABRIL70 ; 12.7% ABRIL210,  $p < 0.05$  for both ABRIL groups vs placebo.
- Response at week 8: 49% ABRIL70, 46.8% ABRIL210 and 25.9% placebo,  $p < 0.05$  for both ABRIL groups vs placebo.
- Mucosal healing at week 8: 32.7% ABRIL70, 29.1% ABRIL210 and 21.6% placebo,  $p < 0.05$

#### Conclusion:

Abrilumab treatment for 8 weeks induced remission, clinical response and mucosa healing in patients with moderate-severe active ulcerative colitis

#### Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis



**Figure 1.** Non-adjusted remission rates for all patients, patients with prior TNF antagonist failure, and patients naïve to TNF antagonist at week 8. Patients received SC placebo or abrilumab 7 mg, 21 mg, or 70 mg (on day 1, week 2, week 4, and Q4W thereafter) or a single dose of abrilumab 210 mg (on day 1 followed by placebo weeks 2 and 4 and Q4W there-

